EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives

Krzysztof Drygalski iD

International Journal of Molecular Sciences · 07.07.2025 · 26 (13) · 6518

DOI: 10.3390/ijms26136518 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.07.2025. Verfasst von Krzysztof Drygalski. Beteiligte Einrichtung: Department of Hypertension and Diabetology, Medical University of Gdansk, ul. Mariana Smoluchowskiego 17, 80-214 Gdańsk, Poland. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly NAFLD, is the most prevalent chronic liver disease worldwide. Strongly linked to obesity, type 2 diabetes, and metabolic syndrome, MASLD poses a growing health burden. Despite its high prevalence and risk of progression, no pharmacological treatment is currently approved. This narrative review provides an overview of emerging pharmacological treatments under clinical investigation, with a particular focus on agents recently evaluated in randomized clinical trials. A systematic search of the ClinicalTrials.gov database through to April 2025 was conducted to identify relevant studies. Investigational drugs were categorized by their molecular mechanisms, and data on efficacy, safety, and clinical development phases were summarized. The most extensively studied drug classes include GLP-1 receptor agonists, PPAR agonists, and FXR agonists, as well as inhibitors of ACC and DGAT. These therapies have shown promising effects on hepatic steatosis, liver enzyme levels, and metabolic markers and may be introduced into clinical practice in the near future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHumansAnimalsGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

MASHMASLDNAFLDNASHtreatment

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Hypertension and Diabetology, Medical University of Gdansk, ul. Mariana Smoluchowskiego 17, 80-214 Gdańsk, Poland.

ORCID-Profile: Krzysztof Drygalski

Zitieren

APA

Drygalski, K. (2025). Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives. International Journal of Molecular Sciences, 26(13), 6518. https://doi.org/10.3390/ijms26136518

Vancouver

Drygalski K. Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives. International Journal of Molecular Sciences. 2025;26(13):6518. doi:10.3390/ijms26136518

BibTeX
@article{Drygalski2025,
  author = {Drygalski, Krzysztof},
  title = {Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {13},
  pages = {6518},
  doi = {10.3390/ijms26136518}
}
Kostenlos starten →